Latest:
Advanced 3D MRI Technology Marks a Leap Forward in Glioblastoma Imaging
Although advances
have been made in
imaging techniques
for patients with glioblastoma
multiforme, new
tools are needed to supplement
standard imaging sequences.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Hui-Zi Chen, MD, PhD
Latest:
Dr. Chen on Rapid Research Autopsy in Rare Cancer
Hui-Zi Chen, MD, PhD, discusses the use of rapid research autopsy in metastatic ultra-hypermutated interdigitating dendritic cell sarcoma, an extremely rare cancer of dendritic origin that lacks a standardized treatment approach.
Hussein A. Tawbi, MD, PhD
Latest:
Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 Years
A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable stage III or IV melanoma.
Hyung L. Kim, MD
Latest:
Dr. Kim on Combining Immunotherapy and TKIs in Metastatic RCC
Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the potential combination of immunotherapy and tyrosine kinase inhibitors in metastatic renal cell carcinoma.
I. Alex Bowman, MD
I. Alex Bowman, MD is a Genitourinary Medical Oncologist at the Banner Gateway Medical Center in Gilbert, AZ.
Latest:
Dr Bowman on Distinctions Between Disease Characteristics and Treatment Response in ccRCC vs Non-ccRCC
I. Alex Bowman, MD, discusses the differences in disease presentation between ccRCC and non-ccRCC, as well as standard treatments for these subtypes.
Ian Chau, MD
Latest:
Dr. Chau on Nivolumab in Asian Versus Western Patients With Gastric/GEJ Cancer
Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the findings of an analysis of nivolumab (Opdivo) in Asian versus Western patients with gastric/gastroesophageal junction (GEJ) cancer.
Ian Davis, MBBS, PhD, FRACP, FAChPM
Latest:
Dr. Davis on the ANZUP Collaboration on the ENZAMET Trial in Prostate Cancer
Ian Davis, MBBS, PhD, FRACP, FAChPM, professor of medicine at Monash University and Eastern Health, and head of the Eastern Health Clinical School, discusses the Australian and New Zealand Urogenital and Prostate Cancer Trials Group collaboration on the randomizedphase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.